Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...